Atlas Venture Fund XI, L.P.'s Form 4 filing
Third Harmonic Bio, Inc.THRD · filed Sep 19, 2022
- Accession no.
- 0001209191-22-050535
- Filed
- Sep 19, 2022, 4:51 PM ET
- Trade date
- Sep 19, 2022
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 4 derivative transactions. Open-market purchases total $5.10M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Atlas Venture Fund XI, L.P.CIK 0001708269 | 10% Owner |
| Atlas Venture Opportunity Fund I, L.P.CIK 0001759241 | 10% Owner |
| Atlas Venture Associates Opportunity I, L.P.CIK 0001780065 | 10% Owner |
| Atlas Venture Associates Opportunity I, LLCCIK 0001780066 | 10% Owner |
| Atlas Venture Associates XI, LLCCIK 0001780067 | 10% Owner |
| Atlas Venture Associates XI, L.P.CIK 0001780068 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 19, 2022 | Common Stock | CConversionAcquired | +6,472,374 | –F1 | – | 10,013,763 | Direct | |
| Sep 19, 2022 | Common Stock | PPurchaseAcquired | +300,000 | $17.00F3 | +$5,100,000 | 10,313,763 | Direct | |
| Sep 19, 2022 | Common Stock | CConversionAcquired | +594,096 | –F1 | – | 594,096 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 19, 2022 | Common Stock | CConversionDisposed | −3,541,390 | –F1 | – | 0 | Direct | |
| Sep 19, 2022 | Common Stock | CConversionDisposed | −2,282,537 | –F1 | – | 0 | Direct | |
| Sep 19, 2022 | Common Stock | CConversionDisposed | −648,447 | –F1 | – | 0 | Direct | |
| Sep 19, 2022 | Common Stock | CConversionDisposed | −594,096 | –F1 | – | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date.
Referenced by the price of 2 transactions in Table I and 4 transactions in Table II.
- F3
On September 19, 2022, Atlas Venture Fund XI purchased 300,000 shares of common stock of the Issuer at a purchase price of $17.00 per share pursuant to an underwritten public offering.
Referenced by the price of 1 transaction in Table I.